Who
James N. Topper
Director and 10% owner
Company insider
Files Form 4 as: Director and 10% owner, Phathom Pharmaceuticals; 10% owner, HilleVax; Director, NewAmsterdam Pharma Company; Director and 10% owner, Alpine Immune Sciences; Director and 10% owner, AnaptysBio; 10% owner, Arcutis Biotherapeutics; Director and 10% owner, Allena Pharmaceuticals; Director and 10% owner, Aptinyx.
In numbers
- Trades disclosed
- 1,098
- Buys
- 77
- Sells
- 4
- Bought
- $113.2M
- Sold
- $370K
- Companies
- 15
- Companies where not an officer
- 15
- First trade
- 18 May 2006
- Last trade
- 19 May 2026
- Last filed
- 21 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 May 2026filed 21 May 2026 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —24,122 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —24,122 at $0.00 | filing |
| 17 Sep 2025filed 17 Sep 2025 | HilleVax | SEC FORM 4 Code U | $16.6M8,535,337 at $1.95 | filing |
| 17 Sep 2025filed 17 Sep 2025 | HilleVax | SEC FORM 4 Code U | $34K17,199 at $1.95 | filing |
| 15 Sep 2025filed 17 Sep 2025 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Bought | $16K660 at $23.70 | filing |
| 8 Sep 2025filed 10 Sep 2025 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Bought | $31K1,260 at $24.99 | filing |
| 11 Aug 2025filed 13 Aug 2025 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Bought | $11K471 at $23.98 | filing |
| 25 Jun 2025filed 26 Jun 2025 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Bought | $23K1,260 at $18.26 | filing |
| 24 Jun 2025filed 26 Jun 2025 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Bought | $46K2,520 at $18.43 | filing |
| 16 Jun 2025filed 18 Jun 2025 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Bought | $167K8,584 at $19.50 | filing |
| 3 Jun 2025filed 5 Jun 2025 | PHAT Phathom Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,500 at $0.00 | filing |
| 3 Jun 2025filed 5 Jun 2025 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —10,500 at $0.00 | filing |
| 21 May 2025filed 23 May 2025 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $15K3,780 at $3.86 | filing |
| 14 May 2025filed 15 May 2025 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $21K6,300 at $3.32 | filing |
| 13 May 2025filed 15 May 2025 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $3,5391,120 at $3.16 | filing |
| 12 May 2025filed 13 May 2025 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $38K12,601 at $3.04 | filing |
| 9 May 2025filed 13 May 2025 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $106K33,376 at $3.19 | filing |
| 9 May 2025filed 13 May 2025 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $8,0582,226 at $3.62 | filing |
| 26 Mar 2025filed 28 Mar 2025 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Bought | $26K1,135 at $22.49 | filing |
| 4 Mar 2025filed 6 Mar 2025 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Bought | $84K4,005 at $21.02 | filing |
The newest 500 lines are listed; the numbers count every line.
News
Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDAPHAT · manilatimes.net · 23 Oct 2026Head to Head Survey: Collegium Pharmaceutical (NASDAQ:COLL) versus Journey Medical (NASDAQ:DERM)COLL · dailypolitical.com · 22 Oct 2026Financial Review: Myriad Genetics (NASDAQ:MYGN) & AnaptysBio (NASDAQ:ANAB)ANAB · tickerreport.com · 20 Oct 2026Phathom Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide Business Update on Thursday, October 29, 2026PHAT · manilatimes.net · 19 Oct 2026Head-To-Head Analysis: Rallybio (NASDAQ:RLYB) versus NewAmsterdam Pharma (NASDAQ:NAMS)NAMS · dailypolitical.com · 14 Oct 2026Analyzing NewAmsterdam Pharma (NASDAQ:NAMS) & Grifols (NASDAQ:GRFS)NAMS · tickerreport.com · 14 Oct 2026Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Stock Has Consensus Price Target of $48.71COLL · dailypolitical.com · 13 Oct 2026Mirum Pharmaceuticals to report Livmarli trial results Monday (MIRM:NASDAQ)MIRM · seekingalpha.com · 12 Oct 2026
0 headlines in the last 90 days name James N. Topper; 9 articles from the last 14 days about the 5 companies they traded most, at most three about any one of them.